biostudies-literatureOgbuagu ONIAID NIH HHSGilead Sciences Ince397-e407https://www.ebi.ac.uk/biostudies/studies/S-EPMC12492902biostudies-literatureUnknown8(7)<h4>Background</h4>In DISCOVER, a multinational, randomised controlled trial, emtricitabine and tenofovir alafenamide compared with emtricitabine and tenofovir disoproxil fumarate showed non-inferior efficacy for HIV prevention and improved bone mineral density and renal safety biomarkers at week 48. We report outcomes analysed after all participants had completed 96 weeks of follow-up.<h4>Methods</h4>This study is an ongoing, randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial done at 94 community, public health, and hospital-associated clinics located in Europe and North America. Adult cisgender men and transgender women who have sex with men, both with a high risk of acquiring HIV as determined by self-reported sexual behaviour or recent sexually traThe lancet. HIVLong-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.PMC12492902P30 AI050410Young BEbrahimi RTaylor SHaas BOsiyemi OPhilibert PSinclair GColeman MHurt CHengel RKronborg GBrainard DMKrznaric ISalazar LOgbuagu OMounzer KSalazar LCBurack JTremblay CGladstein JHosek SHassler SPost FSobieszczyk MKegg STrottier BScarsella ANwokolo NHare CFlamm JDinges WLazzarin ASchembri GWorkowski KAntinori AAsmuth DShao YBrinson CBrunetta JMLarsen CSDoblecki-Lewis SReeves IWhitlock GSpinner CDGilson RGrossberg RHenry WYawetz SRuane PRuane PJCox SClarke ADel Romero Guerrero JHenry KPetroll ARichmond GPodzamczer DRieger AStephens JDISCOVER study teamIandiorio MMills AVoskuhl GDeJesus EHardy WDPhoenix JCua ECarter CColl JBenson PCrespo Casal MBrar IJessen HBergin CSzabo JCreticos CLucasti CMarkowitz MMolina JMRashbaum BAsmuth DMCrofoot GWade BDonovan TCespedes MDaar EGerstoft JGrant RMayer KShalit PSpinner CLeen CScott MAvery AMannheimer Sde Wet JDas MPrins MMorris SGallant JLaMarca ARamgopal MWohl DApea VCampbell TDosekun OCruickshank FMallon PPialoux GBerhe MMartorell CBaeten JMHodge TKintu AThompson MKnecht GHalperin JBrunetta JLarsen ODfalseLong-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.<h4>Background</h4>In DISCOVER, a multinational, randomised controlled trial, emtricitabine and tenofovir alafenamide compared with emtricitabine and tenofovir disoproxil fumarate showed non-inferior efficacy for HIV prevention and improved bone mineral density and renal safety biomarkers at week 48. We report outcomes analysed after all participants had completed 96 weeks of follow-up.<h4>Methods</h4>This study is an ongoing, randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial done at 94 community, public health, and hospital-associated clinics located in Europe and North America. Adult cisgender men and transgender women who have sex with men, both with a high risk of acquiring HIV as determined by self-reported sexual behaviour or recent sexually tra2021-01-01T00:00:00Z2021 Jul2026-06-04T06:54:24.733Z2026-05-06T03:12:18.257ZS-EPMC124929023419777210.1016/S2352-3018(21)00071-010.1016/s2352-3018(21)00071-0